الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Head and neck cancer represent roughly 5% of all new cancer diagnoses. Long term survival is improving with advances in therapy, but outcomes remain suboptimal. This is largely because the majority of patients present with locoregional advanced disease. Surgery was once the mainstay of treatment for all resectable cases but led to significant morbidity. Concurrent chemoradiotherapy has produced improved results in patients with advanced head and neck cancers concerning locoregional control, disease free survival and overall survival more than radiotherapy alone , however more was achieved, especially concerning reduction of distant failure by addition of adjuvant chemotherapy. Cisplatin alone is lower than the combination with taxane in the response rate and disease free survival but the same in overall survival , however we could not ignore the occurrence of some side effects such as mucosits and neutropenia that lead to treatment gap during radiotherapy and delay of some chemotherapy cycles.